Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Bio-Rad Laboratories, Inc. (BIO-B)

    Price:

    310.70 USD

    ( - 0 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    BIO-B
    Name
    Bio-Rad Laboratories, Inc.
    Industry
    Medical - Devices
    Sector
    Healthcare
    Price
    310.700
    Market Cap
    8.381B
    Enterprise value
    10.155B
    Currency
    USD
    Ceo
    Norman D. Schwartz
    Full Time Employees
    7700
    Ipo Date
    1999-09-21
    City
    Hercules
    Address
    1000 Alfred Nobel Drive

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Edwards Lifesciences Corporation

    VALUE SCORE:

    6

    Symbol
    EW
    Market Cap
    48.780B
    Industry
    Medical - Devices
    Sector
    Healthcare

    2nd position

    Stryker Corporation

    VALUE SCORE:

    9

    Symbol
    SYK
    Market Cap
    135.328B
    Industry
    Medical - Devices
    Sector
    Healthcare

    The best

    Abbott Laboratories

    VALUE SCORE:

    9

    Symbol
    ABT
    Market Cap
    218.406B
    Industry
    Medical - Devices
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -12.274
    P/S
    3.250
    P/B
    1.231
    Debt/Equity
    0.207
    EV/FCF
    27.644
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    3.640
    Earnings yield
    -0.081
    Debt/assets
    0.144
    FUNDAMENTALS
    Net debt/ebidta
    -1.606
    Interest coverage
    4.572
    Research And Developement To Revenue
    0.111
    Intangile to total assets
    0.100
    Capex to operating cash flow
    0.315
    Capex to revenue
    0.060
    Capex to depreciation
    3.138
    Return on tangible assets
    -0.077
    Debt to market cap
    0.168
    Piotroski Score
    5.000
    FUNDAMENTALS
    PEG
    0.040
    P/CF
    16.880
    P/FCF
    24.682
    RoA %
    -6.971
    RoIC %
    2.470
    Gross Profit Margin %
    52.263
    Quick Ratio
    5.441
    Current Ratio
    5.441
    Net Profit Margin %
    -26.428
    Net-Net
    -43.953
    FUNDAMENTALS PER SHARE
    FCF per share
    12.508
    Revenue per share
    94.992
    Net income per share
    -25.105
    Operating cash flow per share
    18.254
    Free cash flow per share
    12.508
    Cash per share
    52.765
    Book value per share
    250.225
    Tangible book value per share
    214.304
    Shareholders equity per share
    250.225
    Interest debt per share
    53.649
    TECHNICAL
    52 weeks high
    359.220
    52 weeks low
    225.290
    Current trading session High
    310.700
    Current trading session Low
    310.700
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    -9.28%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -34.924
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -10.111
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Care Facilities
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    11.335
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    27.517
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Healthcare Information Services
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    43.377
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Distribution
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    23.991
    logo

    Country
    IE
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -27.585
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -13.117
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Healthcare Plans
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    10.228
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    74.327
    DESCRIPTION

    Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

    NEWS
    https://images.financialmodelingprep.com/news/biorad-laboratories-macroeconomic-uncertainty-and-a-limited-growth-potential-20250807.jpg
    Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

    seekingalpha.com

    2025-08-07 07:30:00

    The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.

    https://images.financialmodelingprep.com/news/biorad-laboratories-analysts-raise-their-forecasts-after-betterthanexpected-q2-20250801.jpg
    Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

    benzinga.com

    2025-08-01 11:30:23

    Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

    https://images.financialmodelingprep.com/news/biorad-laboratories-beats-quarterly-profit-estimates-on-strong-sales-20241030.jpg
    Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

    reuters.com

    2024-10-30 18:09:54

    Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.

    https://images.financialmodelingprep.com/news/biorad-labs-cuts-annual-revenue-forecast-on-weak-demand-20240801.jpg
    Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

    reuters.com

    2024-08-01 17:56:40

    Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

    https://images.financialmodelingprep.com/news/biorad-laboratories-reiterates-2024-revenue-growth-outlook-shares-slip-20240507.jpg
    Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

    reuters.com

    2024-05-07 18:11:01

    Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.

    https://images.financialmodelingprep.com/news/biorad-labs-cuts-2023-revenue-growth-forecast-as-biotechs-20231026.jpg
    Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending

    reuters.com

    2023-10-26 17:46:56

    Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down about 11% in extended trading.